Otto Metzger

CDK4/6 inhibition triggers anti-tumour immunity

Shom Goel, Molly J. DeCristo, April C. Watt et al. · Nature · 2017 · 1.5K citations · Full text

Medicine, Cancer Biology, Oncology +12

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial

Sibylle Loibl, Joyce O’Shaughnessy, Michael Untch et al. · The Lancet Oncology · 2018 · 771 citations

Medicine, Oncology, Pharmacology +14

Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer

Kamal S. Saini, Sherene Loi, Evandro de Azambuja et al. · Cancer Treatment Reviews · 2013 · 378 citations

Medicine, Oncology, Pharmacology +14

Patterns of Recurrence and Outcome According to Breast Cancer Subtypes in Lymph Node–Negative Disease: Results From International Breast Cancer Study Group Trials VIII and IX

Otto Metzger, Zhuoxin Sun, Giuseppe Viale et al. · Journal of Clinical Oncology · 2013 · 343 citations

Medicine, Oncology, Pathology +16

Genomic Characterization of Primary Invasive Lobular Breast Cancer

Christine Desmedt, Gabriele Zoppoli, Gunes Gundem et al. · Journal of Clinical Oncology · 2016 · 326 citations · Full text

Medicine, Molecular Genetics, Oncology +16